BUFFALO, N.Y. — Research from a team of radiation oncology experts at Roswell Park Comprehensive Cancer Center has been selected as one of the “most clinically relevant” presentations at the annual meeting of the American Society for Radiation Oncology (ASTRO), [held September 27 to October 1] in San Francisco.
The study reports the results of a clinical trial at Roswell Park demonstrating that a single dose of highly precise radiation delivered post-operatively to patients with non-small cell lung cancer provides the same local disease control as the traditional five-week course of radiation — but is less toxic, causing fewer side effects.
Study first author Mark Farrugia, MD, PhD, Clinical Assistant Professor of Oncology in the Department of Radiation Medicine at Roswell Park, will discuss the findings Monday, Sept. 29, in an oral abstract presentation. The work was also included in a Science Highlights Session on Sunday, September 28, featuring top-rated lung cancer abstracts as determined by ASTRO…